MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: GlobeNewswire
Presentations highlight real-world dosing and titration patterns in youth, and post-prandial glucose management strategies using inhaled insulin in both adults and youth with T1DData to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD)PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that new clinical and real-world data related to Afrezza® (insulin human) Inhalation Powder will be presented at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2026), taking place March 11–14, 2026, in Barcelona, Spain. “We
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- MannKind (MNKD) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- MannKind Corporation (MNKD) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- MannKind CEO purchases 100,000 shares; stock climbs [Seeking Alpha]Seeking Alpha
- MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 [Yahoo! Finance]Yahoo! Finance
MNKD
Earnings
- 2/26/26 - Beat
MNKD
Sec Filings
- 3/10/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- MNKD's page on the SEC website